Risk Stratification for Diffuse Large B‐Cell Lymphoma by Integrating Interim 18 F‐FDG PET‐CT Analysis and the NCCN‐IPI: A Multicenter Retrospective Study
Hematological Oncology · 2025-07 · 43 (4)
DOI: 10.1002/hon.70118 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, online erschienen am 07.07.2025. Verfasst von Jiesong Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer I…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Foundation, National Natural Science Foundation of China, Jin Men Medical Talents of Tianjin.
Abstract (Originalsprache)
Our study aimed to assess the prognostic significance of the interim National Comprehensive Cancer Network International Prognostic Index and PET‐CT‐related parameters for predicting patient outcomes and achieving precise risk stratification for diffuse large B‐cell lymphoma (DLBCL) patients. We retrospectively analyzed the clinicopathological and PET‐CT data of 498 patients diagnosed with DLBCL across three medical centers in China. 418 patients were eligible for subsequent analysis after excluding those with incomplete data and 70% of which were randomly selected as the discovery cohort, whereas the remaining 30% constituted the validation cohort. The impact of candidate factors on survival was assessed via univariate and multivariate Cox proportional hazards models. The area under the curve AUC and C‐index were calculated to assess the predictive performance of models. Univariate and multivariate Cox regression analyses identified changes in total lesion glycolysis (ΔTLG), iNCCN‐IPI, interim abdominal residual disease (iARD) status, and changes in the maximum standardized uptake value (ΔSUVmax) as independent prognostic factors. Leveraging the outcomes of the multivariate analysis, we constructed the iPET‐NCCN‐IPI prognostic model and categorized DLBCL patients into two separate prognostic risk groups based on their computed Risk Scores ( RS = 0.90×iNCCN‐IPI + 1.41×ΔTLG + 0.79×ΔSUVmax + 0.83×iARD ). The predictive performance of the model was validated by calculating the area under the receiver operating characteristic curve and the C‐index. Notably, compared with other models, the iPET‐NCCN‐IPI demonstrated superior prognostic capability. In conclusion, our study indicates that the iPET‐NCCN‐IPI stratifies DLBCL patients into two distinct prognostic risk groups and surpasses other models in prognostic predictive ability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Lymphoma and State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, K…
- Department of Lymphoma & Head and Neck Oncology, College of Clinical Medicine for Oncology, Fujian Medical University, Fuzhou, China.
- Kindstar Biotech, Wuhan, China.
- Kindstar Global Precision Medicine Institute, Wuhan, China.
- Department of Nuclear Medicine and PET Center, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
- Department of Nuclear Medicine, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
ORCID-Profile: Jiesong Wang, Huilai Zhang
Förderung
- State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Foundation
- National Natural Science Foundation of China
- Jin Men Medical Talents of Tianjin
- Construction Project of Cancer Precision Diagnosis and Drug Treatment Technology
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Wang, J., Sun, Y., Lin, M., Lyu, Q., Zhai, S., Song, Z., Liu, X., Li, L., Qiu, L., Qian, Z., Wan, X., Zhou, S., Gong, W., Meng, B., Yu, B., He, J., Ye, X., Zhu, L., Wang, X., & Zhang, H. (2025). Risk Stratification for Diffuse Large B‐Cell Lymphoma by Integrating Interim 18 F‐FDG PET‐CT Analysis and the NCCN‐IPI: A Multicenter Retrospective Study. Hematological Oncology, 43(4). https://doi.org/10.1002/hon.70118
Vancouver
Wang J, Sun Y, Lin M, Lyu Q, Zhai S, Song Z, et al. Risk Stratification for Diffuse Large B‐Cell Lymphoma by Integrating Interim 18 F‐FDG PET‐CT Analysis and the NCCN‐IPI: A Multicenter Retrospective Study. Hematological Oncology. 2025;43(4). doi:10.1002/hon.70118
BibTeX
@article{Wang2025,
author = {Wang, Jiesong and Sun, Yong and Lin, Meifu and Lyu, Qinghu and Zhai, Shudan and Song, Zheng and Liu, Xia and Li, Lanfang and Qiu, Lihua and Qian, Zhengzi and Wan, Xing and Zhou, Shiyong and Gong, Wenchen and Meng, Bin and Yu, Bei and He, Jin and Ye, Xiaofei and Zhu, Lei and Wang, Xianhuo and Zhang, Huilai},
title = {Risk Stratification for Diffuse Large B‐Cell Lymphoma by Integrating Interim 18 F‐FDG PET‐CT Analysis and the NCCN‐IPI: A Multicenter Retrospective Study},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {4},
doi = {10.1002/hon.70118}
}
EUVIMED